ACADIA Pharmaceuticals (ACAD) Financials

ACADIA Pharmaceuticals Inc (ACAD) is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative medicines for central nervous system disorders. The company's income statement provides a snapshot of its financial performance over a specific period. ACADIA Pharmaceuticals Inc reported a steady increase in total revenue, reaching $882.3 million in the latest fiscal year. This growth can be attributed to the strong sales of its flagship product, Nuplazid, which is used for the treatment of Parkinson's disease psychosis. The company's gross profit also saw a significant increase, reaching $720.5 million, reflecting its ability to generate revenue and manage costs effectively. ACADIA Pharmaceuticals Inc's net income from stockholders amounted to $155.7 million, indicating its profitability in delivering returns to its shareholders.

The company's balance sheet showcases its financial position, with total assets amounting to $2.1 billion. ACADIA Pharmaceuticals Inc maintains a healthy level of liquidity, with cash equivalents of $620.8 million. Additionally, the company's stockholders' equity stands at $1.4 billion, indicating a strong foundation and support for its operations. ACADIA Pharmaceuticals Inc's total debt and total liabilities are relatively low, amounting to $274.2 million and $687.6 million, respectively. This demonstrates the company's prudent financial management and its ability to meet its obligations. The company's cash flow statement provides insights into its cash generation and utilization. ACADIA Pharmaceuticals Inc reported positive operating cash flow, indicating its ability to generate cash from its core operations. The company also reported positive investing cash flow, indicating its investments in research and development as well as potential acquisitions. ACADIA Pharmaceuticals Inc's financing cash flow represents its capital raising activities, including debt issuance and equity offerings. The company reported a positive financing cash flow, indicating its ability to access capital markets and fund its operations. Lastly, ACADIA Pharmaceuticals Inc reported positive free cash flow, which indicates its ability to generate cash after accounting for capital expenditures. This demonstrates the company's financial strength and potential for future growth.